The new trial, funded by Pfizer, compared the company’s mRNA shot to Fluzone, one of the most widely used seasonal flu ...

Catalent, which was acquired by Novo Nordisk in December, is a leading contract drug manufacturer operating over 30 manufacturing facilities in the U.S. and abroad. The company makes hundreds of ...

With the future of mRNA vaccines secure, an expert discusses the benefits of vaccine platform diversification.

For people younger than 65, U.S.-licensed flu vaccines had an estimated effectiveness of 44% to 54% that season. Among those who completed a 6-month follow-up, the mRNA vaccine had a relative efficacy ...

The mRNA platform offers the advantage of faster vaccine production, which could allow more time to decide on which flu strains to cover.

The new plant will allow the company to execute end-to-end clinical- and commercial-stage production of its mRNA medicines.

Moderna (MRNA) stock is in focus as the company completes U.S. mRNA production network, investing $140M in Massachusetts and ...

New capabilities strengthen U.S. production, completing Moderna's domestic end-to-end mRNA manufacturing network ...

Grim revelations have surfaced from within the Department of Health and Human Services (HHS), exposing a culture of censorship surrounding critical discussions about the COVID-19 vaccine and its ...

Moderna said mNEXSPIKE was approved by the FDA for use in adults aged 65 and up, as well as some individuals aged 12 to 64. Kymera Stock Jumps 41%. New Dermatitis Pill Could Challenge Regeneron ...

Delaware says COVID-19 vaccines are available at state clinics, regardless of insurance status. But only 2 clinics carried ...

Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51) Narrows 2025 projected ...